More recently evidence has also suggested that certain HLA-B leader dimorphisms may impact outcomes, with better rates of GVHD and nonrelapse mortality for those mismatched at the threonine leader (TT genotype) compared to either the methionine genotypes (MM or MT) (54). Here, HLA-B is linked to graft versus host disease.